Showing 1 to 12 of 27 results
Planarian Flatworms Offer Ethical Alternative in Psychiatric Drug Research
Researchers in the UK discovered that planarian flatworms respond to psychiatric drugs similarly to mammals, potentially reducing the need for animal testing while offering insights into developing treatments for schizophrenia and addiction.
Planarian Flatworms Offer Ethical Alternative in Psychiatric Drug Research
Researchers in the UK discovered that planarian flatworms respond to psychiatric drugs similarly to mammals, potentially reducing the need for animal testing while offering insights into developing treatments for schizophrenia and addiction.
Progress
32% Bias Score
AlphaFold 3: Enhanced Protein Modeling Accelerates Drug Discovery
AlphaFold 3, a new protein modeling tool developed by DeepMind, improves upon its predecessor by expanding its capabilities to include ligands, ions, and post-translational modifications, leading to more accurate predictions and faster drug development; its open-source nature (with some limitations)...
AlphaFold 3: Enhanced Protein Modeling Accelerates Drug Discovery
AlphaFold 3, a new protein modeling tool developed by DeepMind, improves upon its predecessor by expanding its capabilities to include ligands, ions, and post-translational modifications, leading to more accurate predictions and faster drug development; its open-source nature (with some limitations)...
Progress
44% Bias Score
New Compound Shows Promise in Targeting Cancer Metastasis
French biochemist Raphael Rodriguez developed Fentomycin-1, a compound that targets cancer metastasis by triggering ferroptosis, showing promising results in lab tests against various cancers, including pancreatic, breast, and sarcoma cancers.
New Compound Shows Promise in Targeting Cancer Metastasis
French biochemist Raphael Rodriguez developed Fentomycin-1, a compound that targets cancer metastasis by triggering ferroptosis, showing promising results in lab tests against various cancers, including pancreatic, breast, and sarcoma cancers.
Progress
40% Bias Score
Cadence and Nvidia Launch AI-Accelerated Millennium M2000 Supercomputer
Cadence Design Systems and Nvidia unveiled the Millennium M2000 Supercomputer, an AI-accelerated simulation platform offering up to 80X performance improvement and 20X lower power consumption versus traditional systems, impacting chip design, drug discovery, data center optimization, and physical AI...
Cadence and Nvidia Launch AI-Accelerated Millennium M2000 Supercomputer
Cadence Design Systems and Nvidia unveiled the Millennium M2000 Supercomputer, an AI-accelerated simulation platform offering up to 80X performance improvement and 20X lower power consumption versus traditional systems, impacting chip design, drug discovery, data center optimization, and physical AI...
Progress
44% Bias Score
New Molecule Reduces Heart Tissue Necrosis, Promising Treatment for Heart Attacks
A joint Russian-Chinese team created a molecule reducing heart tissue necrosis, a leading global death cause, impacting over 700,000 Russians annually; initial testing shows promise, with clinical trials planned.
New Molecule Reduces Heart Tissue Necrosis, Promising Treatment for Heart Attacks
A joint Russian-Chinese team created a molecule reducing heart tissue necrosis, a leading global death cause, impacting over 700,000 Russians annually; initial testing shows promise, with clinical trials planned.
Progress
48% Bias Score
Amgen's Unconventional AI Hire: Nike Data Scientist to Lead Drug Discovery
Amgen, a $151 billion pharmaceutical company, hired Sean Bruich, Nike's data science expert, as its senior vice president for AI and data in August 2023 to accelerate drug discovery and operational efficiency, reflecting the industry's growing reliance on AI and cross-industry talent acquisition.
Amgen's Unconventional AI Hire: Nike Data Scientist to Lead Drug Discovery
Amgen, a $151 billion pharmaceutical company, hired Sean Bruich, Nike's data science expert, as its senior vice president for AI and data in August 2023 to accelerate drug discovery and operational efficiency, reflecting the industry's growing reliance on AI and cross-industry talent acquisition.
Progress
48% Bias Score
AI Designs Novel Antibiotics to Combat Drug-Resistant Superbugs
MIT researchers used AI to design two new antibiotics effective against drug-resistant gonorrhea and MRSA in lab and animal tests; however, human trials are years away.
AI Designs Novel Antibiotics to Combat Drug-Resistant Superbugs
MIT researchers used AI to design two new antibiotics effective against drug-resistant gonorrhea and MRSA in lab and animal tests; however, human trials are years away.
Progress
40% Bias Score
French Firm Aqemia Speeds Cancer Drug Development with AI and Physics
Aqemia, a French firm founded in 2019, uses AI and physics to accelerate drug molecule creation for head, neck, and thorax cancers; collaborating with Sanofi, Servier, and Johnson & Johnson, it aims for faster, more cost-effective drug development.
French Firm Aqemia Speeds Cancer Drug Development with AI and Physics
Aqemia, a French firm founded in 2019, uses AI and physics to accelerate drug molecule creation for head, neck, and thorax cancers; collaborating with Sanofi, Servier, and Johnson & Johnson, it aims for faster, more cost-effective drug development.
Progress
44% Bias Score
Curie Institute Researcher Develops Novel Cancer Therapy Targeting Iron-Dependent Metastasis
Raphaël Rodriguez, a CNRS research director at the Curie Institute, discovered that metastatic cancer cells' high iron and copper ion demand makes them vulnerable to oxidation, leading to the development of a molecule inducing 'ferropoptosis', a novel therapeutic approach published in Nature.
Curie Institute Researcher Develops Novel Cancer Therapy Targeting Iron-Dependent Metastasis
Raphaël Rodriguez, a CNRS research director at the Curie Institute, discovered that metastatic cancer cells' high iron and copper ion demand makes them vulnerable to oxidation, leading to the development of a molecule inducing 'ferropoptosis', a novel therapeutic approach published in Nature.
Progress
36% Bias Score
Human Brain Tissue Mimics Alzheimer's, Accelerating Cure Search
British scientists used living human brain tissue from cancer patients undergoing surgery to model the early stages of Alzheimer's disease, exposing it to amyloid beta proteins and observing its inability to repair the damage; this breakthrough accelerates drug testing and enhances prospects for a c...
Human Brain Tissue Mimics Alzheimer's, Accelerating Cure Search
British scientists used living human brain tissue from cancer patients undergoing surgery to model the early stages of Alzheimer's disease, exposing it to amyloid beta proteins and observing its inability to repair the damage; this breakthrough accelerates drug testing and enhances prospects for a c...
Progress
48% Bias Score
Living Brain Tissue Used to Model Alzheimer's, Accelerating Cure Search
A British team used living human brain tissue exposed to a toxic Alzheimer's-linked protein to observe real-time damage to brain cell connections, providing a new method to test potential treatments and accelerate the search for a cure for this disease affecting millions worldwide.
Living Brain Tissue Used to Model Alzheimer's, Accelerating Cure Search
A British team used living human brain tissue exposed to a toxic Alzheimer's-linked protein to observe real-time damage to brain cell connections, providing a new method to test potential treatments and accelerate the search for a cure for this disease affecting millions worldwide.
Progress
24% Bias Score
AlphaFold Revolutionizes Drug Discovery
AlphaFold, a DeepMind AI, predicts protein 3D structures in minutes, accelerating drug discovery and research; its database of 250 million structures has been used by almost 2 million researchers, leading to discoveries like a new liver cancer drug and a molecular syringe.
AlphaFold Revolutionizes Drug Discovery
AlphaFold, a DeepMind AI, predicts protein 3D structures in minutes, accelerating drug discovery and research; its database of 250 million structures has been used by almost 2 million researchers, leading to discoveries like a new liver cancer drug and a molecular syringe.
Progress
48% Bias Score
Showing 1 to 12 of 27 results